Merck (MRK) Net Cash Flow (2009 - 2026)

Merck has disclosed Net Cash Flow across 18 years of filings, most recently posting -$9.3 billion for Q1 2026.

• In Q1 2026, Net Cash Flow fell 95.55% year-over-year to -$9.3 billion; the TTM figure through Mar 2026 stood at -$3.7 billion (down 221.63% YoY), while the FY2025 annual figure was $809.0 million, down 87.93% from the prior year.
• Net Cash Flow fell to -$9.3 billion in Q1 2026, from -$3.6 billion in the prior quarter.
• Over the last five years, Net Cash Flow for MRK reached as high as $10.2 billion in Q3 2025 and fell as low as -$9.3 billion in Q1 2026.
• The 5-year median for Net Cash Flow is -$1.0 billion (2024), against an average of -$154.9 million.
• Annual changes were most pronounced in 2023 — Net Cash Flow slumped 712.35% — and 2024, when it soared 245.29%.
• A 5-year view of Net Cash Flow shows it stood at $1.1 billion in 2022, then plunged by 272.52% to -$1.9 billion in 2023, then soared by 48.46% to -$1.0 billion in 2024, then plunged by 258.23% to -$3.6 billion in 2025, then plunged by 158.09% to -$9.3 billion in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$9.3 billion, -$3.6 billion, and $10.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.